SJS Investment Consulting
RNAC icon

SJS Investment Consulting’s Cartesian Therapeutics RNAC Stock Holding History

SJS Investment Consulting’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$959 Buy
133
+112
+533% +$975 ﹤0.01% 2513
2026
Q2 		$219 Buy
21
+19
+950% +$141 ﹤0.01% 2458
2026
Q1 		$13 Buy
+2
New +$14 ﹤0.01% 2410

Other funds holding RNAC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Fedenia Advisers
Fedenia Advisers Madison, Wisconsin $425M AUM 89.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Wedbush Securities
Wedbush Securities Los Angeles, California $3.95B AUM 25.45% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

SJS Investment Consulting's RNAC Position: Q3 2026 in Review

SJS Investment Consulting increased its Cartesian Therapeutics (RNAC) stake by 533% in Q3 2026, buying an estimated $975 and bringing the position to 133 shares worth $959. The position accounts for ﹤0.01% of the portfolio, ranked #2513.

SJS Investment Consulting first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • SJS Investment Consulting held 133 shares of Cartesian Therapeutics worth $959 as of Q3 2026.
  • SJS Investment Consulting bought 112 Cartesian Therapeutics shares in Q3 2026, an estimated $975.
  • Cartesian Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2513 holding.
  • SJS Investment Consulting first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 30 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.